FDA Advisory Committee Provides Opinion On Serdolect® For The Treatment Of Schizophrenia

H. Lundbeck A/S (LUN.CO; LUN DC) announced that the Psychopharmacology Drug Advisory Committee (PDAC) appointed by the U.S. Food and Drug Administration (FDA) voted unanimously that Serdolect® (sertindole) is efficacious in the treatment of patients with schizophrenia, though they did not find the data robust enough to support an additional regulatory claim related to treatment of suicidal behaviour in schizophrenia.

More: continued here

Filed under: Clinical Trials on April 10th, 2009